Covert preleukemia driven by MLL gene fusion

Genes Chromosomes and Cancer

Volumn 48, Issue 1, 2009, Pages 98-107

  Zuna, Jan ^a   Burjanivova, Tatiana ^a   Mejstrikova, Ester ^a   Zemanova, Zuzana ^b   Muzikova, Katerina ^a   Meyer, Claus ^c   Horsley, Sharon W ^d   Kearney, Lyndal ^d   Colman, Susan ^d   Ptoszkova, Hana ^e   Marschalek, Rolf ^c   Hrusak, Ondrej ^a   Stary, Jan ^a   Greaves, Mel ^d   Trka, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b University of Prague   (Czech Republic)

^c GOETHE UNIVERSITY   (Germany)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MIXED LINEAGE LEUKEMIA PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; MLL PROTEIN, HUMAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW; BONE MARROW CELL; CASE REPORT; CONTROLLED STUDY; FEMALE; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENETIC LINE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMOGENESIS; LYMPHATIC LEUKEMIA; MOLECULAR CLONING; PRELEUKEMIA; PRIORITY JOURNAL; STEM CELL; CANCER STEM CELL; CHROMOSOME 19; CHROMOSOME ANALYSIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROMYELOCYTIC LEUKEMIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; CHROMOSOMES, HUMAN, PAIR 19; CYTOGENETIC ANALYSIS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, LEUKEMIC; GENE FUSION; GENE REARRANGEMENT; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MYELOID CELLS; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASTIC STEM CELLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRELEUKEMIA; TUMOR MARKERS, BIOLOGICAL;

EID: 58149374011     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20622     Document Type: Article

References (35)

1. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB. 1995. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9: 1783-1786.
2. Bernard OA, Hillion J, Le Coniat M, Berger R. 1998. A new case of translocation t(6;11)(q21;q23) in a therapy-related acute myeloid leukemia resulting in an MLL-AF6q21 fusion. Genes Chromosomes Cancer 22:221-224.
3. Biondi A, Cimino G, Pieters R, Pui CH. 2000. Biological and therapeutic aspects of infant leukemia. Blood 96:24-33.
4. Blanco JG, Dervieux T, Edick MJ, Mehta PK, Rubnitz JE, Shurtleff S, Raimondi SC, Behm FG, Pui CH, Relling MV. 2001. Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci USA 98:10338-10343.
5. Bower M, Parry P, Carter M, Lillington DM, Amess J, Lister TA, Evans G, Young BD. 1994. Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. Blood 84:3776-3780.
6. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. 1999. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96:857-868.
7. Burjanivova T, Madzo J, Muzikova K, Meyer C, Schneider B, Votava F, Marschalek R, Stary J, Trka J, Zuna J. 2006. Prenatal origin of childhood AML occurs less frequently than in childhood ALL. BMC Cancer 6:100.
8. Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, Reiter A, Ritter J, Dworzak M, Stary J, Rein-hardt D. 2006. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: Results of AML-BFM 98. J Clin Oncol 24:4499-4506.
9. Drynan LF, Pannell R, Forster A, Chan NM, Cano F, Daser A, Rabbitts TH. 2005. Mll fusions generated by Cre-loxP-medi-ated de novo translocations can induce lineage reassignment in tumorigenesis. EMBO J 24:3136-3146.
10. Eguchi M, Eguchi-Ishimae M, Knight D, Kearney L, Slany R, Greaves M. 2006. MLL chimeric protein activation renders cells vulnerable to chromosomal damage: An explanation for the very short latency of infant leukemia. Genes Chromosomes Cancer 45:754-760.
11. Felix CA. 1998. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1400:233-255.
12. Ford AM, Ridge SA, Cabrera ME, Mahmoud H, Steel CM, Chan LC, Greaves M. 1993. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363:358-360.
13. Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB, Greaves MF. 1997. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 94:13950-13954.
14. Greaves MF, Maia AT, Wiemels JL, Ford AM. 2003. Leukemia in twins: Lessons in natural history. Blood 102:2321-2333.
15. Hillion J, Le Coniat M, Jonveaux P, Berger R, Bernard OA. 1997. AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. Blood 90: 3714-3719.
16. Horsley SW, Colman S, McKinley M, Bateman CM, Jenney M, Chaplin T, Young BD, Greaves M, Kearney L. 2008. Genetic lesions in a preleukemic aplasia phase in a child with acute lymphoblastic leukemia. Genes Chromosomes Cancer 47:333-340.
17. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R. 1999. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074-3080.
18. Leblanc T, Hillion J, Derre J, Le Coniat M, Baruchel A, Daniel MT, Berger R. 1994. Translocation t(11;11)(q13;q23) and HRX gene rearrangement associated with therapy-related leukemia in a child previously treated with VP16. Leukemia 8:1646-1648.
19. Maia AT, Koechling J, Corbett R, Metzler M, Wiemels JL, Greaves M. 2004. Protracted postnatal natural histories in childhood leukemia. Genes Chromosomes Cancer 39:335-340.
20. Medema RH, Kops GJ, Bos JL, Burgering BM. 2000. AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404:782-787.
21. Megonigal MD, Cheung NK, Rappaport EF, Nowell PC, Wilson RB, Jones DH, Addya K, Leonard DG, Kushner BH, Williams TM, Lange BJ, Felix CA. 2000. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci USA 97:2814-2819.
22. Metzler M, Strissel PL, Strick R, Niemeyer C, Roettgers S, Borkhardt A, Harbott J, Ludwig WD, Stanulla M, Schrappe M, Reinhardt D, Creutzig U, Beck JD, Rascher W, Repp R, Langer T. 2004. Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 41:291-296.
23. Metzler M, Staege MS, Harder L, Mendelova D, Zuna J, Fron-kova E, Meyer C, Flohr T, Bednarova D, Harbott J, Langer T, Gesk S, Trka J, Siebert R, Dingermann T, Marschalek R, Nie-meyer C, Rascher W. 2008. Inv(11)(q21q23) fuses MLL to the notch co-activator mastermind-like 2 in secondary T-cell acute lymphoblastic leukemia. Leukemia 22:1807-1811.
24. Meyer C, Schneider B, Reichel M, Angermueller S, Strehl S, Schnittger S, Schoch C, Jansen MW, van Dongen JJ, Pieters R, Haas OA, Dingermann T, Klingebiel T, Marschalek R. 2005. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci USA 102:449-454.
25. Meyer C, Schneider B, Jakob S, Strehl S, Attarbaschi A, Schnittger S, Schoch C, Jansen MW, van Dongen JJ, den Boer ML, Pieters R, Ennas MG, Angelucci E, Koehl U, Greil J, Griesinger F, Zur Stadt U, Eckert C, Szczepanski T, Niggli FK, Schafer BW, Kempski H, Brady HJ, Zuna J, Trka J, Nigro LL, Biondi A, Delabesse E, Macintyre E, Stanulla M, Schrappe M, Haas OA, Burmeister T, Dingermann T, Klingebiel T, Marschalek R. 2006. The MLL recombinome of acute leukemias. Leukemia 20:777-784.
26. Nemoto N, Suzukawa K, Shimizu S, Shinagawa A, Takei N, Taki T, Hayashi Y, Kojima H, Kawakami Y, Nagasawa T. 2007. Identification of a novel fusion gene MLL-MAML2 in secondary acute myelogenous leukemia and myelodysplastic syndrome with inv(11)(q21q23). Genes Chromosomes Cancer 46:813-819.
27. Ng A, Ravetto PF, Taylor GM, Wynn RF, Eden OB. 2004. Coexistence of treatment-related MLL cleavage and rearrangement in a child with haemophagocytic lymphohistiocytosis. Br J Cancer 91:1990-1992.
28. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E, van der Schoot CE, van Dongen JJ. 1998. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 12:2006-2014.
29. Robinson BW, Cheung NK, Kolaris CP, Jhanwar SC, Choi JK, Osheroff N, Felix CA. 2008. Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome. Blood 111:3802-3812.
30. So CW, Cleary ML. 2003. Common mechanism for oncogenic activation of MLL by forkhead family proteins. Blood 101:633-639.
31. Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, For-mankova R, Mejstrikova E, Stary J, Trka J. 2007. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 48:93-100.
32. Takei N, Suzukawa K, Mukai HY, Itoh T, Okoshi Y, Yoda Y, Nagasawa T. 2006. Therapy-related acute myeloid leukemia 6 years after clonal detection of inv(11)(q21q23) and MLL gene rearrangement. Int J Hematol 83:247-251.
33. Takeuchi M, Nakaseko C, Miyagi S, Takeda Y, Ozawa S, Ohwada C, Cho R, Nishimura M, Saito Y, Iwama A. 2008. Clo-nal expansion of non-leukemic cells expressing two novel MLL-ELL variants differing in transforming activity. Leukemia 22:861-864.
34. Teuffel O, Betts DR, Thali M, Eberle D, Meyer C, Schneider B, Marschalek R, Trakhtenbrot L, Amariglio N, Niggli FK, Scha-fer BW. 2005. Clonal expansion of a new MLL rearrangement in the absence of leukemia. Blood 105:4151-4152.
35. Wiederschain D, Kawai H, Shilatifard A, Yuan ZM. 2005. Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage. J Biol Chem 280: 24315-24321.